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Abstract
Despite the plethora of empirical studies conducted to date, debate continues about whether
and to what extent results should be returned to participants of genomic research. We
aimed to systematically review the empirical literature exploring stakeholders’ perspectives
on return of individual research results (IRR) from genomic research. We examined prefer-
ences for receiving or willingness to return IRR, and experiences with either receiving or
returning them. The systematic searches were conducted across five major databases in
August 2018 and repeated in April 2020, and included studies reporting findings from pri-
mary research regardless of method (quantitative, qualitative, mixed). Articles that related to
the clinical setting were excluded. Our search identified 221 articles that met our search cri-
teria. This included 118 quantitative, 69 qualitative and 34 mixed methods studies. These
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articles included a total number of 118,874 stakeholders with research participants (85,270/
72%) and members of the general public (40,967/35%) being the largest groups repre-
sented. The articles spanned at least 22 different countries with most (144/65%) being from
the USA. Most (76%) discussed clinical research projects, rather than biobanks. More than
half (58%) gauged views that were hypothetical. We found overwhelming evidence of high
interest in return of IRR from potential and actual genomic research participants. There is
also a general willingness to provide such results by researchers and health professionals,
although they tend to adopt a more cautious stance. While all results are desired to some
degree, those that have the potential to change clinical management are generally priori-
tized by all stakeholders. Professional stakeholders appear more willing to return results
that are reliable and clinically relevant than those that are less reliable and lack clinical rele-
vance. The lack of evidence for significant enduring psychological harm and the clear bene-
fits to some research participants suggest that researchers should be returning actionable
IRRs to participants.
Introduction
Although next generation sequencing technologies (NGS) were implemented in the research
setting well over a decade ago, debate continues about whether and to what extent results from
genomic research should be returned to participants. An individual research result (IRR)
broadly refers to any finding that arises from the research endeavour, which can include: 1)
study-specific results (i.e., results related to the condition under investigation; SSR), 2) unsolic-
ited findings (i.e., disease-causing variants unrelated to the genetic condition under investiga-
tion that are identified inadvertently during the research study; UF), 3) secondary findings
(i.e., disease-causing variants unrelated to the genetic condition under investigation that are
actively searched for by the research team; SF).
A plethora of empirical studies show that participants have high interest in receiving indi-
vidual research results (IRR) [1–13]. A recent policy on Clinically Actionable Genomic
Research Results from the Global Alliance for Genomics and Health (GA4GH), has advocated
for return of results to participants, arguing that an ethical and legal consensus on this point is
emerging [14]. Yet, there remains a degree of hesitancy from some research projects and bio-
banks to return IRR to participants, the reasons for which are numerous, complex, and con-
text-dependent. Examination of the reasons for the hesitation to return IRR will help us
understand the challenges researchers and other professional stakeholders either foresee, or
are experiencing in the return process, which will then enable the development of systems to
support this process.
Although some authors have postulated that drawing a distinct boundary between the
research and clinic contexts is inappropriate in translational genomics [15–17], we believe it is
important to explore the issue of return of results between the two settings separately. While
we acknowledge that there is significant overlap between the clinic and the research setting in
some situations [17], including hybrid models such as the 100,000 Genomes project [18], we
argue that what differs between the two is the primary goal of the genetic analysis. The primary
goal of testing in the clinical setting is to identify any potential underlying genetic contribu-
tions to the condition seen in the patient, or to provide genomic risk information in healthy
individuals, and is performed under the auspices of clinical care and established guidelines. In
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research, the primary goal is to generate knowledge and, in certain circumstances, a secondary
goal of using the results to guide clinical care is also present [19]. This distinction arises
because the duty of care that a clinician has to their patients is different to the responsibilities a
researcher has to a research participant. This distinction applies even to a clinician-researcher,
depending on their relationship with the patient-participant. It equally suggests that the degree
to which it is appropriate or necessary to return particular types of results, such as unsolicited
findings, secondary findings and variants of uncertain significance (i.e., variants that could
potentially be the cause of the genetic condition under study but where existing evidence is
insufficient to classify the variant as either (likely) benign or (likely) pathogenic; VUS) [20],
will be different between the two contexts. It is important to recognize that in the clinical set-
ting, results that are returned to patients can be positive (i.e., a cause has been identified), nega-
tive (i.e., a cause has not been identified), or uncertain (i.e., something has been found but its
clinical significance cannot be determined). Yet, in the context of research, a result that is
returned will almost always be positive; participants are unlikely to be informed that nothing
has been found. For these reasons, there is a need to focus specifically on the research setting,
where the necessity and appropriateness of returning findings to patients may be less distinct.
Previous literature reviews relating to return of results have not only chosen to include pub-
lications that reported on return of SF in both clinical and research settings, they also focused
purely on return of SF [21] rather than return of IRR overall. Although SF are an important
type of IRR, the majority of results identified through genomic research will be either study-
related or identified inadvertently through the course of the research. As such, a comprehen-
sive understanding of stakeholder perspectives on receiving all types of IRR is required.
The legal and regulatory landscape regarding return of results currently comprises a patch-
work of often contradictory rules for researchers, especially where research collaborations
stretch across countries and continents as many now do in the field of genomics. In their
recent review, Thorogood et al identified sufficient discrepancies between policies to prevent
reconciliation of rules about which results should or should not be returned in research proj-
ects [22]. Moreover, they found that policies, including thresholds for data quality and clinical
significance, were evolving in uneven ways, further complicating policy development for
return of results. Thorogood et al call for greater clarity in the ethical and policy approach to
return of results. We argue that such clarity must be based on the actual wishes and perspec-
tives of those most affected by policy development for return of results.
To address these gaps, we aimed to systematically review the empirical literature exploring
stakeholders’ (i.e., participants, patients, publics, health professionals, researchers, Institutional
Review Boards (IRBs), or mixed professionals; for definitions see Table 1) perspectives and
experiences with return of individual results from genomic research to examine the interest in
receiving, or willingness to return IRR, and experiences with receiving or returning IRR.
Methods
In 2018, the four lead authors (DFV, JTM, SJR, MJM) registered a systematic review protocol
on Prospero (https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=117551).
Two authors (JTM, SJR) formulated a search strategy to identify studies reporting 1) stake-
holders’ views on whether or not research participants, and potentially their relatives, should
receive individual genomics findings, 2) which findings should be returned and the reasons
for such opinions and perspectives, and 3) experiences with either receiving IRR or returning
them to research participants. This search strategy was reviewed and refined by the other two
lead authors (MJM and DFV). Searches were conducted across five major databases in August
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2018 and repeated in April 2020 and then again in May 2021 (see Fig 1). Details about search
terms used can be found in S1 Table.
The review considered studies reporting findings from primary research regardless of
method (quantitative, qualitative, mixed). Specific articles were included if they were published
from 2005 onwards; in English; contained empirical data; and related to the return of results
from genomic research in a research (not clinical) context, which also included biobanks, as
well as both germline and somatic research testing. Articles that incorporated both clinical and
research settings were included. Articles were rejected if they were opinion-based or review
papers; related only to clinical or diagnostic sequencing; discussed solely the return of raw data
(i.e., not annotated/interpreted); related only to the direct-to-consumer context; or related
only to carrier screening or neonatal genomic screening, rather than diagnostic testing, even
when part of a research protocol.
For the 2018, 2020 and 2021 search results, the lead authors independently screened titles
(and abstracts as necessary) for all records identified once duplicates had been removed. Full
text articles were consulted where it remained unclear whether the article met the inclusion
criteria. Full text screening was then undertaken for all articles thought to meet the inclusion
criteria. Each record/article was screened by at least two lead authors, and disagreements were
resolved through discussions among at least three of the lead authors.
For articles identified in 2018, data extraction was undertaken by 19 members of the Return
of Results Task Team of the Regulatory and Ethics Work Stream of the Global Alliance for
Genomics and Health (GA4GH). All were active data and/or health researchers in North
Table 1. Glossary of stakeholder, setting and context definitions.
Stakeholders Definition
Participants Respondents’ views on return of research results elicited based on their position as a
participant of a research study, regardless of whether or not they were offered results.
Patients (and parents of
patients)
Respondents’ views on return of research results elicited based on their clinical status
as a patient. This includes parents of patients in the case of minors.
Publics Respondents’ views on return of research results elicited based on their position as a
member of the community.
Health professionals Respondents recruited based on their status as a health professional, with or without
genetics training.
Researchers Respondents recruited based on their status as a researcher, although some also had




Respondents were members of institutional review boards, including general
members, chairs and coordinators.
Mixed professionals Respondents included individuals from different professional groups, including (but
not limited to) health professionals, researchers, medical centre representatives and
government representatives.
Setting
Clinical research Respondents were asked to consider their views on return of research results within
the context of a clinical research setting (i.e., studies undertaken to investigate the
genetic basis of disease whether or not they were research participants).
Biobanks Respondents were asked to consider their views on return of research results within
the biobank setting, regardless of whether or not they were biobanks participants.
Context
Hypothetical / Policy /
Practice
Respondents were asked to make hypothetical decisions about whether or not they
wished to receive results and, in some cases, which results they wished to receive.
Actual decisions Respondents were asked to decide whether or not they wished to receive results and, in
some cases, which results they wished to receive. This applied both to those who had
and had not received their results at the time of the study.
https://doi.org/10.1371/journal.pone.0258646.t001
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America, Europe, Asia or Australia. Each volunteer was randomly assigned six articles and
provided with an extraction form and instructions developed by the lead authors. Data from
remaining articles was extracted by two authors (JTM, MJM). The extraction form requested
study details, participant characteristics, main findings and conclusions, relevant references,
and reviewers’ assessment of relevance to the research question and of the quality of the article
(see S2 Table). Where only some of an article’s content was eligible for inclusion, only this data
was extracted and included for synthesis. Data extractors were provided with a written over-
view of the study aims and criteria for article inclusion. They were instructed to complete all
fields of the data extraction form for each of their allocated articles and, when entering the
‘Key findings’ section, to only insert data that was relevant to the research question. Data
extractors were encouraged to seek clarity from the lead authors via email where necessary.
Once complete, each form was screened for completeness by JTM before being indepen-
dently quality checked, including checking the quality assessment of each paper, against the
article by one of the other lead authors. During the extraction process, three articles were
removed for not meeting the inclusion criteria, while five articles identified from reference
lists were deemed eligible for full data extraction. No articles were excluded due to poor qual-
ity. This process was repeated twice: in April 2020, the initial search process was repeated to
identify new publications since 2018. Full data extraction was conducted by two authors (JTM,
MJM) and two volunteers (JC, MM). All articles were quality checked by DFV. In this instance,
Fig 1. PRISMA flowchart. From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred
Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097.
doi:10.1371/journal.pmed1000097 For more information, visit www.prisma-statement.org.
https://doi.org/10.1371/journal.pone.0258646.g001
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ten articles were removed during extraction for not meeting the inclusion criteria, while 17
were identified from reference lists as eligible for full extraction. In May 2021, this process was
updated once more, with ten articles again removed and eight identified through reference
lists. For this final cycle, data extraction was conducted by two authors (JTM, MJM) and
checked by a third (DFV). Across all three searches, every record/article was ultimately
assessed in full by at least two reviewers by the end of the screening and extraction process.
Given the number and diversity of studies and methodologies covered by the review, no
single or combination of existing disciplinary or methodologically appropriate quality
appraisal tools could enable valid or rational comparison between the studies. Instead, we
employed a reason-based approach derived from the bioethics literature to evaluate and cri-
tique the “literature in a transparent and systematic way in order to provide a comprehensive
and unbiased overview of the information sought” [23]. To account for the heterogeneity of
methodologies, assessment was based on the transparency of findings, methodological appro-
priateness and coherence of the findings with the methodological approach. We assessed the
clarity and appropriateness of the methodology on the following aspects: study description,
methods, methodology, analysis and conclusions [24]. All articles were broadly appraised for
quality by the data extractors during the data extraction process. All articles were further
reviewed for quality by DFV, JTM and MJM during the checking processes.
We used content analysis to enable systematic analysis of the methodologically diverse arti-
cles in this review [25, 26]. Data extracted from the articles were analyzed using inductive con-
tent analysis in which content categories were derived from the data, rather than pre-
determined [27–29]. The data were coded into broad content categories, such as ‘preferences
and expectations for return of study-specific results’, ‘preferences for unsolicited or secondary
findings’ and ‘experiences receiving or returning results’. Subcategories were delineated within
these broad categories in two stages: 1) based on the stakeholders from which the perspectives
were gained, 2) based on study setting (i.e., clinical research versus biobanks). Note was also
taken about whether the stakeholder perspectives were gauged in a hypothetical/policy con-
text, whether they were being asked to make decisions about results that would be returned in
the future, or where results were returned. Data were coded and interpreted by DV using
Word documents; MM analysed subsets of the data to confirm the coding scheme.
Results
Our search identified 221 articles that met our search criteria. This included 97 (53.4%) quanti-
tative, 54 (31.2%) qualitative and 32 (15.4%) mixed methods studies (Figs 2 and 3). These arti-
cles included a total number of 118,874 stakeholders with research participants (85,270/72%)
and members of the general public (40,967/35%) being the largest groups represented. The
articles spanned at least 17 different countries with most (125/65%) being from the USA (Figs
4 and 5). A high proportion (76%) related to research projects as distinct from the biobank set-
ting. More than half (58%) gauged views that were hypothetical. A complete list of the articles
and their characteristics, such as participant numbers and country of origin, can be found in
Table 2. A summary of the study demographics can be found in Table 3.
Here we present the data for three data categories from our analysis that correspond with
our research question: 1) views on return of study-specific results; 2) views on return of UF
and SF findings; 3) experiences with receiving IRR (participants) or returning results (health
professionals). Data are presented grouped by stakeholder, by setting, and in relation to study
context (i.e., whether the participants were being asked to comment on return of results in a
hypothetical/policy setting or whether they were being asked to make real decisions about
receiving or returning results).
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1. Views on return of study-specific results
Summaries of interest in receiving SSR for participants, patients (and their parents), and mem-
bers of the public can be found in Table 4.
1.1 Participants’ preferences for receiving study-specific results
Clinical research setting. Overall, participants, and parents of children participating in
genomic research studies, generally have strong preferences for, or expectations to receive
SSR. Those wanting results that are related to the research question ranged from 47.6% [10] to
97% [6]. Percentages seemed to depend on the genetic condition being studied, whether the
decision to receive results was hypothetical or actual (either with or without results having
been returned), and the framing of the question. Receiving SSR was also highlighted by partici-
pants as a high motivation for participation [30, 32, 64], based on the hope of a cure for them-
selves and future generations [65].
Fig 2. Number of articles by research method.
https://doi.org/10.1371/journal.pone.0258646.g002
Fig 3. Number of participants by research method.
https://doi.org/10.1371/journal.pone.0258646.g003
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Investigating a hypothetical context, a study of 103 racially diverse adult patients with late-
stage kidney disease participating in a genomic study showed that 62.13% felt it was very
important to receive genetic and health results related to the condition under study, with only
a small proportion (11.7%) indicating return of results was not important at all [3]. Likewise,
in a study of 241 persons with mental disorders, 95% wanted ‘pertinent’ findings to be made
available [13]. Studies have shown that participants without an existing health condition are
highly interested in receiving all categories of results [5] and generally prefer ‘knowing’ to ‘not
knowing’ [40]. Yet, a US-based study of 311 mostly healthy volunteers, referred to as the Clin-
Seq study, indicated that interest was highest for receiving results for treatable/preventable
conditions and carrier status [5]. This accords with other studies where respondents have been
most interested in receiving information about genes that are life-threatening or may increase
their risks for future health problems, where preventable options are available, or that are likely
Fig 4. Number of articles by country.
https://doi.org/10.1371/journal.pone.0258646.g004
Fig 5. Number of participants by country.
https://doi.org/10.1371/journal.pone.0258646.g005
PLOS ONE Systematic review of stakeholder perspectives on return of results









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































PLOS ONE Systematic review of stakeholder perspectives on return of results






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































PLOS ONE Systematic review of stakeholder perspectives on return of results

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































PLOS ONE Systematic review of stakeholder perspectives on return of results













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































PLOS ONE Systematic review of stakeholder perspectives on return of results






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































PLOS ONE Systematic review of stakeholder perspectives on return of results





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































PLOS ONE Systematic review of stakeholder perspectives on return of results
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































PLOS ONE Systematic review of stakeholder perspectives on return of results

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































PLOS ONE Systematic review of stakeholder perspectives on return of results



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































PLOS ONE Systematic review of stakeholder perspectives on return of results






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































PLOS ONE Systematic review of stakeholder perspectives on return of results












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































PLOS ONE Systematic review of stakeholder perspectives on return of results


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































PLOS ONE Systematic review of stakeholder perspectives on return of results







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































PLOS ONE Systematic review of stakeholder perspectives on return of results















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































PLOS ONE Systematic review of stakeholder perspectives on return of results















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































PLOS ONE Systematic review of stakeholder perspectives on return of results



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































PLOS ONE Systematic review of stakeholder perspectives on return of results

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































PLOS ONE Systematic review of stakeholder perspectives on return of results





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































PLOS ONE Systematic review of stakeholder perspectives on return of results




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































PLOS ONE Systematic review of stakeholder perspectives on return of results















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































PLOS ONE Systematic review of stakeholder perspectives on return of results



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































PLOS ONE Systematic review of stakeholder perspectives on return of results













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































PLOS ONE Systematic review of stakeholder perspectives on return of results






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































PLOS ONE Systematic review of stakeholder perspectives on return of results























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































PLOS ONE Systematic review of stakeholder perspectives on return of results


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































PLOS ONE Systematic review of stakeholder perspectives on return of results
PLOS ONE | https://doi.org/10.1371/journal.pone.0258646 November 8, 2021 33 / 71









Total 221 100 118,874 100
Study type
Quantitative 118 53.4% 103,883 87.4%
Qualitative 69 31.2% 2,591 2.2%
Mixed methods 34 15.4% 12,400 10.4%
Country
Australia 5 2.3% 2,157 1.8%
Bangladesh 1 0.5% 200 0.2%
Botswana 1 0.5% 105 0.1%
Canada 12 5.4% 1,063 0.9%
Denmark 5 2.3% 8,099 6.8%
Estonia 2 0.9% 27 0.0%
Finland 2 0.9% 272 0.2%
France 1 0.5% 261 0.2%
India 1 0.5% 43 0.0%
Ireland 1 0.5% 351 0.3%
Italy 2 0.9% 1,628 1.4%
Japan 4 1.8% 7,076 6.0%
Jordan 1 0.5% 3,196 2.7%
Kenya 1 0.5% 63 0.1%
Netherlands 5 2.3% 2,096 1.8%
Singapore 1 0.5% 280 0.2%
South Africa 2 0.9% 678 0.6%
Sweden 2 0.9% 354 0.3%
Switzerland 1 0.5% 25 0.0%
UK 11 5.0% 1,619 1.4%
USA 144 65.2% 79,698 67.0%
Zambia 1 0.5% 21 0.0%
Multi-country 15 6.8% 9,562 8.0%
Context
Biobanks 61 27.6% 47,487 39.9%




23 10.4% 14,944 12.6%
Review Boards 13 5.9% 2,822 2.4%
Researchers 40 18.1% 15,042 12.7%
Research
Participants
153 69.2% 85,270 71.7%
Public 36 16.3% 40,967 34.5%
Situation type
Hypothetical/Policy 129 58.4% 96,416 81.1%
Decision made 38 17.2% 23,736 20.0%
Results returned 71 32.1% 17,164 14.4%
� The total number of papers or participants in the various groupings below is sometimes greater than 221 and
118,874 respectively. This is because: (1) papers were frequently assigned to multiple categories (e.g. a biobank and
research context; decision made and results returned); and (2) study participants were similarly assigned more than
once (e.g. interview and survey). Some percentage totals are thus also greater than 100%.
https://doi.org/10.1371/journal.pone.0258646.t003
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to change their doctor’s approach to their care [3, 40]. Yet desires for information persist for
some participants, both with and without existing medical conditions, even when options for
return of information include diseases without known prevention, treatment, or other action-
ability, and genes with uncertain significance [3, 5, 66, 67]. A study of 219 cognitively normal
adults enrolled in longitudinal aging studies indicated that 51.9% wanted Apolipoprotein E
(APOE) genotype, despite the fact that Alzheimer’s disease is non-actionable [7].
With hypothetical scenarios, there was a strong preference for results in parents of children
participating in research [68]. Interviews with 25 parents of children in an exome sequencing
study at the National Institute of Health (NIH) showed that all participants wanted to receive
their children’s results [11]. Similarly, 97% of 362 parents of children with rare inherited child-
hood diseases or pediatric cancer who were participating in one of three large-scale genome
research consortia stated a positive right to receive SSR [6].
High levels of interest in learning about results were also expressed by participants making
actual decisions about whether they wanted to receive results [1, 2, 12]. Several studies
observed that return of results was a key reason for research participation [2, 4, 69, 70] and a
survey exploring participation across several Clinical Sequencing Exploratory Research
(CSER) consortium sites showed that only 5% who declined did so because they did not want
research results returned [71]. In a study of 263 veterans and 1,159 non-veteran adult Mexi-
can-Americans enrolled in genetic family studies aimed at identifying increased susceptibility
to diabetes and diabetic nephropathy, 95.7% and 93.1% respectively expressed interest in
receiving their SSR [1]. Similarly, in a study of adolescents aged 14–18 years who were either
undergoing treatment for substance and conduct problems (SCPs; n = 320) or were non-SCP
controls (n = 109), most participants (77.8% of SCPs and 72.5% of non-SCPs) wanted to know
results if there were health or behavioral implications [4].
In general, very low proportions of participants– 8.2% of 790 undiagnosed adults and chil-
dren with conditions suspected to have a primarily monogenic cause and 3% of 506 adult
members of families at high genetic risk for cancer–refused all results [72, 73]. However, some
studies highlighted that some participants only want results when investigators have assessed
the risks and benefits of sharing results with them (68/271; 25.1%), or if the results would be
useful for their doctor’s decision-making (74/271; 27.3%) [10]. Surveys and interviews with 35
participants from New York showed that 94% wanted to receive all categories of results [12].
Yet, when participants were asked to nominate which categories of results they wished to
receive, 100% wanted pharmacogenetics information, but only 74% wished to receive results
regarding conditions which were unpreventable [12]. Studies have found that adults [74] and
parents [75, 76] may be uncertain about which results they want and what to do with them.
Although 85% of 154 parents of children recruited to studies investigating genetic causes and
novel therapeutics for rare diseases, indicated they had a strong/very strong right to receive
results, even in situations when the possibility of an ameliorative therapy was uncertain [77],
Table 4. Summaries of articles that address stakeholder interest in receiving study-specific results.
Stakeholder Setting Interest in IRR Publications
Participants Clinical Research 48% to 97% [1–13, 30–32]
Biobank 57% to 96% [33–41].
Patients/parents Clinical Research 61% to 98% [13, 34, 42–50]
Biobank 53.5% to 88% [50–52]
Public Clinical Research 73% to 95% [13, 44, 49, 53–59]
Biobank 91% to 98% [60–63]
https://doi.org/10.1371/journal.pone.0258646.t004
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others did not wish to receive results that could not be interpreted or were non-actionable/
incurable for their children [78].
Two studies that returned results at study completion–one with 107 men and women from
families with a known mismatch repair (MMR) gene mutation and the other with 31 adult par-
ticipants from the ClinSeq cohort who had received one sequencing result with personal health
implications–showed that 79% and 80.6% respectively elected to receive results at the start of
the study [8, 9]. A third study of 31 healthy individuals, conducted by Stanford University,
showed that receiving exome results to learn more about their health risks was the most com-
mon reason for participation [79]. A further study of 162 adults who had a living or deceased
parent with Alzheimer’s disease and were randomized to receive or not receive their own
APOE genotype showed that some participants randomized to the nondisclosure group were
dissatisfied at not receiving their genotyping results [80].
Participants from all these studies present a range of reasons for wanting to receive SSR,
which are summarised in Table 5. These reasons differ slightly depending on the condition
under investigation and whether the research testing was being conducted in adults or their
children. For example, parents of children in an exome sequencing study at the NIH wanted
results to identify an explanation for their child’s condition, provide information about their
child’s health, coordinate better management for their child’s condition, and prepare for their
child’s future healthcare needs [11]. Some wanted answers from genomic sequencing to lead
to treatments [75]. Parents also described feelings of responsibility toward their children and
desires for control associated with receiving the results [11]. In contrast, adult participants
want SSR in order to have greater certainty about personal risk [8, 30], to determine whether
they required screening [8], because it was recommended by their healthcare professional or
desired by a relative [8], or for insurance or planning purposes [8, 30, 88]. Participants also
listed a desire to know health information [5, 12, 81], provide diagnostic certainty [82], prevent
disease/improve health [5, 12, 81, 86, 88], adopt better health habits [88] and alter medical
management as reasons for wanting their results [5, 82].
In a hospital-based study of genetic susceptibility to melanoma, 68% of 19 participants
wanted to know their personal risk so they could discuss it with their doctor, so they could use













Reasons for wanting to receive
results
For health information, clinical
utility, disease prevention, or to
improve health or medical
management
[5, 12, 45, 81–
86]





Identify cause of child’s current/
future condition, informed about
child’s health and care









[69, 87, 88] [48] [95] [91, 92,
97]
[96]
Responsibility or moral obligation
to children or family
[11, 36] [75, 87]
To inform their children and other
family members
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Planning and insurance purposes [8, 30, 36] [88] [42] [95]
Motivation for change or healthier
lifestyle
[36] [69, 88, 99] [42]




Understanding of personal risk, to
know if need screening, so can
discuss with doctor
[8, 30, 83]
Family or personal history of a
disease
[5] [87, 99]
Family planning [69, 85, 101] [96]
Personal utility [36] [102]
Reassurance, peace of mind,





Desire for control [11] [99]
Right to know own or child’s
results
[95] [94]
To participate in a clinical trial [103]
Promotion of autonomy [92]
To improve population health or
public health knowledge
[92]
Advocate for clinical services [96]
Reduce stigma [96]
Shows participation is valued [86]
Reasons for not wanting to
receive results
Potential for adverse psychological
impact






Implications for children (e.g.
insurance, legal, privacy)
[12, 101] [69, 75]
Balancing benefits and risks of
knowing
[69, 75]
Participants may not wish to know [106] [94]
May become overly vigilant/lead to
unnecessary appointments
[88]
Inability to make health changes [85]
Concerns about availability of





Concerns about privacy [84, 85, 106]




Do not consider themselves to be at
risk
[97]
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it for preventative purposes (58%), or wanted reassurance that they were not at increased risk
(37%). Yet almost half (47%) also wanted to receive results out of curiosity [83]. This interest
in receiving results out of curiosity was supported in the study of healthy participants by San-
derson et al [12]. In addition, 74% wanted results to be able to inform their children [83], a
finding which has also been recognised by others, along with a desire to tell other family mem-
bers [12] and for family planning purposes [69, 101]. The ClinSeq study indicated that a pro-
portion were motivated to receive results by their family history of a particular disease [5]. In
addition, adults enrolled in the Dominantly Inherited Alzheimer’s Network want SSR in order
to participate in a clinical trial [103]. Interestingly, in a study of 246 cancer patients and 315
participants who had a family history of Alzheimer’s disease (but no disease themselves), par-
ticipants said they would be more likely to want to know their results if they knew the research-
ers already had access to that information [107]. Yet, participants from three other studies also
raised concerns about receiving IRR due to the potential for adverse psychological impact of
receiving results that have implications for future health [2, 12], and implications of results for
their children, including the impact on insurance, legal issues and privacy [12, 101].
1.1 Participants’ preferences for receiving study-specific results
(continued)
Biobank setting. Participants in the context of biobanks also express high interest in SSR,
with between 57% and 98% wanting results to be returned [33–41, 84, 85, 106, 108–111]. Par-
ticipants generally expressed higher interest in results that conveyed some sort of actionability
[33, 34, 39–41, 112]. For example, in a study of 555 biobank participants recruited in the con-
text of clinical care appointments, 90% wanted results for conditions that are treatable, com-
pared to 64% who wanted results for non-treatable conditions [33]. These participants also
showed a preference for receiving results that conveyed high disease risk over low disease risk
(79% vs 66%), and risk of serious disease over less serious disease, (83% vs 68%). Yet, 57%
expressed interest in receiving uncertain results. This is in contrast to a study which conducted
interviews and focus groups with 26 female breast cancer patients who had previously given
consent to donate blood or tissue samples to a tissue bank for breast cancer research, in which
most participants did not want to receive results of uncertain clinical significance [113].
Another study, which used a discrete choice experiment to survey 351 participants from a
Swedish research program, identified a preference to receive life threatening disease risk over
other diseases (such as physical disability, mental disease, and physical disease) [40]. They
found greater willingness to learn disease risks when the estimate of penetrance was higher,
and also when the recipient is able to implement lifestyle changes rather than medical inter-
ventions; this proportion increased as did the effectiveness of the interventions [40].
A study of 55 family decision makers who had authorized the donation of deceased loved
ones’ tissue, and 22 requesters recruited through an organ procurement organization, showed
that 94.3% favored the return of results suggestive of treatable diseases and 84.9% for diseases
that could affect their children, compared to 71.7% for non-treatable diseases [39]. Likewise, a
study of biobank participants from two regions in Japan also highlighted that the majority of
respondents (88.2% from region 1 and 82.3% from region 2) preferred to receive their own
genetic information [41]. Interest was highest for diseases that could be modified by lifestyle,
as well as adult-onset and actionable conditions, with much less interest expressed in receiving
pharmacogenetics and adult-onset non-actionable results [41]. Yet, a second Japanese study
conducted an educational workshop with 112 participants and showed that scores for interest
in receiving five categories of results–lifestyle diseases, pharmacogenetics, adult-onset non-
clinically actionable diseases, non-clinically actionable multifactorial diseases, and all genetic
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information–significantly decreased after the workshop [114]. However, even in the face of
this decrease, over 95% still wanted to know results for the diseases that could be influenced by
lifestyle, pharmacogenetics, and adult-onset clinically actionable diseases [114]. In addition, 17
parents of healthy children participating in a biobank wanted to know both childhood- and
adult-onset medically actionable conditions for their child and felt it was more important to
protect their child’s health than preserve their future autonomy [115]. However, one study of
53 young adult participants from the Avon Longitudinal Study of Parents and Children
(ALSPAC) showed only mild interest in receiving SSR and only if they were of clinical rele-
vance [116].
Despite the overall high interest in receiving SSR, studies suggest that expectations for their
return differ. Interviews with 109 NUgene biobank participants showed that while 1/3 hoped
to be recontacted with results, 1/3 expected results to be returned only if something severe was
found, and 1/3 had no expectation that they would be recontacted [117]. This is important as
participants were told during the consent process that it was extremely unlikely that they
would be contacted with research results that could have a significant impact on their health.
A study of 3630 adults, which included 464 biobank participants with a diagnosis of pancreatic
cancer, indicated that 62.1% expect to receive SSR; high proportions of participants held
expectations that they would be told about ‘bad’ stuff (e.g., health risks for conditions), rather
than ‘good’ stuff (e.g., things that do not have associated health risks) [34]. Yet, interviews with
17 cancer patients, 6 first degree relatives and 7 cancer-free controls showed that while many
felt researchers should return research reports to patients, over half said there was no moral
obligation to do so [37].
Four studies explicitly explored participants reasons for wanting to receive SSR in the bio-
bank setting [36, 84]. They identified benefits to participants’ and their families’ health [36,
85], motivation to adopt healthier lifestyles [36], earlier diagnosis or prevention [36, 84], and
improvements in chances for better treatment as key reasons for wanting results [36, 84]. Par-
ticipants also mentioned personal utility, finding meaning in knowing their own or their fam-
ily members’ genetic information, the possibility for future planning [85], including taking out
long term insurance [36] and family planning, a sense of obligation or responsibility to their
family, having ownership over their results [85], and wanting to be a good parent to their chil-
dren [36].
1.2 Patients’ (and parents of patients’) preferences for receiving study-
specific results
As with research participants, patients (and also parents of patients in the case of children)
generally express high interest (between 53.5% and 98%) in return of SSR [13, 34, 42–50, 118,
119]. This applied in both the clinical research and biobanks settings.
Clinical research setting. In a study of 904 participants from the US-based Northwest
Cancer Genetics Registry, which included 340 patients with cancer, participants strongly
endorsed that researchers have an ethical obligation to return results that would affect their
health or health care [44]. A study of 205 patients attending an outpatient clinic in the USA
showed a significant increase (p<0.001) in interest to participate in a hypothetical genomic
research study when they were told that results would be offered following study completion
[48]. Sixty-eight percent of these respondents said they would want results returned for heart
disease, 67% for diabetes type 2, 70% for cancer and 61% for obesity [48]. Another study of 25
adult parents of children who were inpatients at a pediatric hospital, showed that 64% of
parents wanted results for both preventable and non-preventable conditions returned, whereas
35% just wanted to receive results for preventable conditions for their children. Similarly, 76%
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of parents wanted both severe and non-severe conditions, 16% wanted results suggesting
severe conditions only, and 8% only wanted results for non-severe conditions returned [42].
Yet, a study of patients with mental disorders showed that patients and family members were
willing not to receive findings if doing so would compromise the research [13].
Patients discuss wanting to know their results out of personal curiosity [48] or peace of
mind [89], because it may provide personal health benefit [48], clinical utility [89] or action-
ability [42, 52], or to inform their children of their risks [89]. A qualitative study of 25 parents
highlighted that participants considered ‘actionability’ as a broad concept, encompassing
aspects such as medical interventions, lifestyle modifications, education, mental preparation,
and planning, including insurance, housing, and finances [42].
Biobank setting. In contrast to the findings of Sundby et al., in a study of 1903 pancreatic
cancer patients, their spouses, and other blood relatives, 76.3% of patients said that regardless
of the cost, researchers should offer results to research participants [49]. Surveys with 2,960
parents of children from Boston Children’s Hospital felt that results would reduce stress over a
search for the child’s diagnosis and help them look out for symptoms for early screening [52].
One study has suggested that parents are interested in receiving more information about their
children than about themselves; 84.6% of 1060 parents/guardians of children who had received
care at Boston Children’s Hospital indicating they probably or definitely wanted to receive
SSR about themselves and 88% wanting them for their children [50]. Interest reduced consid-
erably when asked to specify the categories of results they wanted.
1.3 Publics’ preferences for receiving study-specific results
As identified in studies on both participants and patients, several studies identified return of
SSR as a reason for participation by members of the public [45, 56, 58, 60, 62, 91, 120]. This
applied to both clinical research and biobank contexts. For example, a hypothetical study of
4659 adult Americans showed that offering SSR was associated with the largest increase in will-
ingness to participate in clinical research–greater than factors such as the study being low-bur-
den and offering higher compensation [62]. In fact, ¾ of respondents said they would be less
willing to participate if SSR were not returned [62]. However, focus groups conducted with 89
members of the general public showed that not all respondents saw returning SSRs as a condi-
tion of research participation, with a small number believing the purpose of the research was
to study health within the population rather than benefiting individuals [91].
Clinical research setting. A large number of studies have assessed public views on return
of SSR in the context of clinical research. Overall, interest in SSR is high [44, 91, 121–124],
ranging from 73–100% [13, 49, 53, 54, 57–59]. Although some studies showed high support
for receiving all types of results [121], the most support has been shown for results relating to
an increased risk of an actionable, treatable, or preventable condition [59, 91, 125, 126] but
also for conditions that are do not currently have treatment options [53, 91]. While some stud-
ies have suggested that respondents favour receiving results for serious conditions [91, 124],
responses to results concerning life-threatening or fatal disorders have been mixed [124].
However, respondents in a study of 100 adults, who were recruited based on the fact they had
never worked in genetics, disagreed with the idea that that definition of benefit for returning
SSR should be limited to clinical benefit [122].
Studies also indicate members of the public wish to receive information about non-medical
traits and information that could change over time [91]. In fact, 59% of respondents in the
Dutch study stated that researchers have a duty to inform participants about mutations, even
when the consequences for their health are unclear [125]. Interestingly, the magnitude of risk
did not appear to be relevant for most respondents in one study, with many suggesting they
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wanted to receive information about both very highly elevated and also only slightly elevated
risks of conditions [91].
Studies show that members of the public express a range of reasons for wanting to receive
their SSR. Some of these are based in desires to improve health, such as that having results can
directly help treat or avoid disease or can motivate them to plan or take action relating to their
health, now or in the future [56, 91–93]. Some held expectations that results would impact on
the management of their existing conditions, or those of their family members [59]. Yet, for
others, results were wanted more out of curiosity, or because they felt a sense of ownership or
empowerment from knowing the information in their genes [91, 97]. One study utilized a
deliberative strategy with 19 Alaska Native and American Indian community members [92].
These stakeholders desired results for individual purposes, such as promotion of autonomy,
privacy, empowerment to make informed decisions, early detection of disease, and improved
preventative care, but also to empower and improve health at the population level and increase
public health knowledge [92].
However, interest in SSR is not universal. One study of 1418 members of the general public
in Missouri indicated that only 12.5% were extremely interested in receiving results regardless
of whether there was an available treatment [7]. In another US-based study of 1515 respon-
dents, 12% stated that they would not want or need any SSR to be returned and 56% agreed it
would be fair to only receive results that were treatable or preventable [53]. Respondents also
showed less interest in receiving results relating to common diseases or that showed major
changes in disease risk [53]. Assessment of attitudes of 41 African American parents in Wash-
ington, showed that only 15% wanted SSR that could provide answers about an illness or
health condition they were currently affected by [59]. In the same study, 26% of non-African
American parents did not want to receive any results for themselves or their children [93].
A large proportion of public sentiment behind not wanting to receive SSR appears to be
based in concern for the implications of the information, both for personal mental health but
also more broadly. Studies have shown that some members of the public fear what they may
learn from the results, and that this could lead to distress, depression, or an inability to cope
with the information [56, 59, 91, 93]. This was particularly the case with untreatable conditions
due to the inevitability that the condition would develop and lack of control over its course
[91]. Others expressed concerns about availability of health, life and long-term care insurance
and that an SSR might not be actionable if a person were to lose their health insurance [56, 59].
Some respondents were concerned about the potential for inaccurate or uncertain results [56,
93], whereas others either ‘felt healthy’ or did not have a family history and therefore did not
consider themselves to be at risk [97].
1.3 Publics’ preferences for receiving study-specific results (continued)
Biobank setting. Members of the public generally express high hypothetical preferences
(91–98%) for receiving SSR from biobanks [60–63]. This is the case both for themselves and
also for their children, as evidenced by a study of 141 individuals across 15 focus groups
where, of the 7 focus groups that discussed return of children’s results, members of 6 of the
groups said that some or all of results of children <18 years should be returned to their parents
[61]. Desires to receive SSR related to all types of findings; of 4659 adult Americans surveyed,
91% wanted to receive results about health risks, regardless of their actionability, 95% wanted
to know if they were at increased genetic risk for something treatable (e.g., asthma), 96%
wanted to know if they were at increased genetic risk for something untreatable (e.g., Alzhei-
mer’s disease), and 96% wanted to know if they were at increased genetic risk for “a bad reac-
tion to certain types of medicine” [62]. A study of 45 adult African American caregivers of
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children recruited through a health centre showed that 89% were interested in receiving IRR
for asthma, 93% for Alzheimer’s disease, 80% for a gene change shown to be more common in
a racial group, and 82% for SSR with uncertain significance [56]. Another article citing the
same research cohort also indicated that SSR for non-actionable results were met with more
opposition than those that were actionable and that, although respondents generally desired
information about Alzheimer’s and dementia, they did not wish receive information about
other mental disorders [55].
Yet, some respondents were "ambivalent" about return of SSR from biobanks, suggesting
that they donate altruistically and therefore would not feel entitled to receive them [127]. Some
respondents suggested they would not want SSR because it would be “too much information”
(8%), because IRR predicting future illness would worry them (17%) or were just “not that
interested” (7%) [62]. Respondents have also been quite divided in their interest to receive
results concerning life-threatening or fatal disorders [55].
1.4 Mixed professionals’ views on returning study-specific results
Clinical research setting. Three studies assessed views of a range of professionals in the
clinical research context [18, 128, 129]. For two of these, a large proportion of their cohort was
comprised of researchers. As such, they have been discussed within the researcher stakeholder
section below. The third interviewed 14 senior professionals from the Netherlands and the UK
with expertise a range of areas, such as clinical care, genetics research, molecular genetics, and
health care management [129]. The professionals held varying views about whether there was
a duty to recontact participants in response to SSR. While some felt there was no duty because
research and clinical care have different aims, others felt that the preferences of the participants
should guide whether results are returned [129]. Issues such as workload burdens and difficul-
ties identifying to whom results should be returned were also raised.
Biobank setting. At an interactive workshop, a group of 9 human research ethics commit-
tees (HREC) members, 10 researchers, 3 health consumers, and 7 "others" including genetic
counselors and members of genetic support groups, were asked about their views on returning
biobank results to participants [130]. Professionals were generally not supportive of returning
results because of the additional time and resources it would require and the difficulties
obtaining consent for result return [130]. In contrast, a study of 17 Dutch key figures in the
field with a mixture of disciplinary backgrounds suggested more positive views towards
returning results to biobank participants [131]. Participants suggested that individual findings
for which treatment options are available should be reported regardless of parental wishes but
that late onset non-treatable conditions in children should not be returned [131]. Views varied
considerably depending on the background of the participant. Biobank experts felt it was
important to distinguish between validated, health-related, and actionable findings compared
to those without health-related significance. Medical practitioners in the study felt an obliga-
tion to return these findings, but not others [131]. Patient representatives were more liberal
with which information should be disclosed to parents than other participants [131].
1.5 Health professionals’ views on returning study-specific results
Three studies deliberately sought to explore health professionals’ views on returning SSR [13,
127, 132].
Clinical research setting. Two studies explored views relating to the clinical research set-
ting. One study which included 74 psychiatrists and 28 clinical geneticists showed that clinical
geneticists and psychiatrists were less positive about receiving any kinds of findings for them-
selves compared to people with mental disorders or relatives [13]. Psychiatrists and clinical
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geneticists were also less positive about receiving genomic findings compared with blood
donors. The second study, which interviewed 25 pediatric and adult physicians and non-
genetic specialists (in oncology and cardiology), suggested that these practitioners only wanted
to receive results for their patients where clear actions could be taken, such as the identification
of earlier interventions or new care pathways [132]. However, the clinicians also had a number
of concerns about returning results to patients. Some of these related to potential for harm to
participants, such as anxiety or distress, false negatives, turning healthy individuals into
‘patients-in-waiting’, subjecting people to unnecessary investigations, and genetic discrimina-
tion. Yet other concerns related to their own lack of preparedness to return the results and pro-
vide support and the extra time required [132].
Biobank setting. One study, which assessed views of healthcare providers working in
both public and private practice on return of results from biobanks, suggested that they felt
biobank participants had a strong right to know results [127]. However, they also reported
being conflicted because the results also have implications for family members, flagging that
result recipients require proper support and guidance with how to manage them.
1.6 Researchers’ views on returning study-specific results
Clinical research setting. Seventeen studies have investigated views of researchers on
returning IRR [44, 76, 84, 119, 18, 128, 133–143]. A study of 39 psychiatric genetic researchers
from 17 countries indicated that the majority of participants were either not returning results
at all or had returned results but were not doing so in a systematic way [137]. In a study of 74
genomics researchers (which included medical geneticists, genetics researchers, and clini-
cians), only 8.1% said results should not be returned [134], and interviews with 23 researchers
(both clinical and non-clinical) who investigate Autism Spectrum Disorder generally felt that
results that explain the cause of autism should be disclosed [76]. High support for return of
results was seen in other studies [44, 137, 142].
Researchers were more supportive of returning results if they explain the cause of the con-
dition under study [76], relate to treatable or preventable conditions [137, 142], and have clini-
cal utility [134], clinical relevance [135], or if the result is available as a clinical test [134].
However, one study also showed support for returning results that provided non-medical
actionability (54%) because it could lead to behavior change or because patients had a right to
know [136]. Another study showed some support for results that are medically relevant but
not actionable (45%) and higher support for returning risk for Huntington disease (71%) and
Alzheimer’s disease risk (64%) for planning purposes [142]. There was very little support for
returning VUS. Researchers also discussed other benefits of returning results, such as the abil-
ity to allow for early interventions [136], plan their futures [137], to improve quality of life
[136], and the potential to lower their environmental risks for psychiatric disease and reduce
stigma associated with mental illness [136]. Researchers also suggested returning results shows
respect for patient-participant autonomy and recognizes participants’ ownership of their data
[142].
However, despite these favourable views, others raised concerns about the uncertainty of
the information being returned to participants [137, 140], the potential impact on scientific
progress [140], burden on researchers who cannot provide the necessary support [136] or lack
of infrastructure and resources [143], and blurring lines between research and clinical care
[136, 140]. Others held concerns for participants’ privacy and confidentiality [128, 137], dis-
crimination from insurance companies and banks [143], their ability to retain control of their
data [137] and ensuring informed consent [18, 137]. In addition, researchers were worried
about the potential for adverse psychological reactions from returning results, including worry
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[136], confusion [136, 137], anxiety, guilt [137], and stigmatization [137]. Respondents in one
study raised concerns that returning IRR would mean that participants use the information to
make clinical decisions, which would then place clinical demands on researchers [139].
Another study stressed the need for results to be disclosed by a physician who can explain the
significance of the findings and the importance of results being communicated to participants
in a personalized manner [84]. In addition, two studies suggested that relatively high propor-
tions of researchers were not giving consideration to returning results to participants [133,
135]. One study of 105 genetics/genomics researchers indicated that, at the time, only 54% had
considered the issue of returning research results, 28% had offered to return IRR, and only two
of these incorporated this into the study planning [135].
1.6 Researchers’ views on returning study-specific results (continued)
Biobank setting. Five studies assessed views of researchers on returning SSR to biobank
participants [144–148]. The first, a study of 80 researchers involved in biobanks, showed that
74% reported that biobank participants only need to be informed of results if they have treat-
ment or prevention implications and 95% reported that it was fine for participants not to find
out about SSR where health implications are unclear [145]. This could be related to the fact
that 81% were concerned that returning results might frighten patient-participants and 66%
believed that information on genetic variation could influence insurance premiums. In addi-
tion, 91% of respondents stated that patients are not more entitled than healthy participants to
receive SSR (defined in the study as ‘genetic variations that in some form or other may be rele-
vant for a specific individual participant’) [145].
Another study, which assessed views of 10 directors of Cooperative Group cancer clinical
trial biobanks, showed that all participants completely disagree that the Cooperative Group
Bank should be responsible for disclosure of results to patients, a view which was heavily influ-
enced by lack of adequate funding to accommodate this process [144]. In contrast, of 18
researchers involved in pediatric biobanking from 10 different countries in the third study,
most researchers wanted to keep connections with patients that had biospecimens and data
stored to be able to provide them (or their relatives) with relevant information from ongoing
research projects [146]. Interviews with 19 researchers from Saudi Arabia showed differing
views: some thought returning SSR was a moral and professional duty whereas others felt
returning results was not consistent with the goals of medical research [148].
1.7 Institutional Review Boards’ views on returning study-specific results
Clinical research setting. Five studies, all from North America, explored views of IRBs on
the return of SSR [44, 149–152]. Generally, members of IRBs thought that research findings
should be returned, provided participants want to know their results [44, 150]. However, while
in one study 15/22 (68%) agreed that participants should ‘probably’ or ‘definitely’ be offered
the choice to receive results that may be useful for participants’ or family’s health [151],
another study indicated that a large majority of the 65 Chairs of US IRBs studied favoured
offering the result to participants, even if there is a lack of clear utility associated with the find-
ings [149]. One study explored views of a cohort of Canadian IRB members, coordinators, and
chairs on returning IRR [152]. They found 50% (30/60) supported returning results when they
indicated a probable medical condition or explanation for a response to a medication [152].
Interestingly, a study of 208 IRB professionals and 351 human genetic researchers showed that
in two separate scenarios, IRB professionals were more likely to agree that individual research
results should be returned to participants than researchers [44].
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Biobank setting. One study addressed views of IRBs on the return of results related to
study-specific results in the biobank setting. An Indian interview-based study of 21 ethics com-
mittee members and 22 researchers, showed that IRB members were unsure about their duty
to review SSR and make decisions about their return [147]. They also held concerns about the
need for a counselor or physician to convey research findings and participants suggested bio-
banks could have a coordinating centre that could assist interactions between sample donors
and researchers, including playing a role in return of findings [147].
2. Views on return of unsolicited and secondary findings
2.1 Participants’ preferences for receiving UF or SF
Clinical research context. Research participants generally expressed high interest in
receiving UF, with values in most studies ranging from 61–100% depending on the nature of
the UF [6, 11, 13, 66, 69, 71, 72, 87, 153–158]. Although participants were keen to receive all
types of UF [77, 154, 158, 159], studies that asked respondents to specify which types of UF
they wished to receive showed participants were most interested in receiving those that could
have implications for their health [66, 156]. For example, a study of 58 adult volunteers in an
ongoing family study of bipolar disorder showed that 97% wanted to receive UF that could
have health implications [66]. However, 83% of the cohort still desired UF regardless of
whether they were actionable. Similarly, responses from 219 adult parents of affected children
who were receiving whole exome sequencing indicated that while 73% wanted to know all UF,
this increased to between 93% and 97% for UF for which there was effective treatment and
intervention, such as breast and ovarian cancer, hemochromatosis, arrhythmia, and cardiomy-
opathy [156]. However, these parents also expressed high interest in results that conveyed no
personal disease risk information, such as pharmacogenetics (98%), carrier status (95%), and
ancestry (96%). Positive views towards receiving carrier status have been shown by others
[104, 155, 160].
A study of 362 parents of children with rare inherited childhood diseases or pediatric cancer
also indicated elevated interest in UF for non-treatable fatal conditions relating to themselves
(83%), which was only slightly lower than their interest in UF for fatal treatable/preventable
conditions (87%) [6]. Yet, while 92% of this group wanted to know about UF for treatable con-
ditions in their child, this dropped to 65% for non-treatable conditions and only 70% wanted
to know uncertain results. This lower interest to receive SF for non-treatable conditions also
seems to be reflected in adults. A study of 152 of ‘cognitively intact adults’ offered SF showed
that while 76% of participants intended to learn some or all categories of SF and values ranged
from 61–63% for receiving pharmacogenetic, carrier status, SNPs, and APOE variants, this
dropped to 49% for rare, highly penetrant, unpreventable/untreatable, progressive conditions
[155]. In contrast, of 149 parents of children recruited to studies investigating genetic causes
and novel therapeutics for rare diseases, only 15% decided they did not want to receive UF that
indicated risk of death in their children [77].
Studies indicate that participants (or their parents in the case of minors) want to receive UF
for health-related planning and to be prepared [69, 87], to make lifestyle changes [69], out of
curiosity [87] or because they are information seekers [69], because they have personal experi-
ence with health conditions, or because feel obligations to family members [87]. Some parents
may also feel a moral obligation toward their children [75] or believe UF will provide them
with a better understanding of the primary condition [100]. Interestingly, a study of 241 per-
sons with mental disorders showed that although 91% thought that participants should receive
UF, they believed that researchers should not actively search for SF [13].
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However, three studies showed results that were not in line with the general trend. These
included a study of 25 parents of children who had exome sequencing study of which only
50% wanted to learn UF relating to carrier status for children [11] and another which found
that 16/23 (70%) parents were ambivalent about genomic sequencing, predominantly due to
the possibility of UF [75]. The third exception was the study of 16 patient-participants with
rare disease (or parents) who were offered the option to receive SF which identified mixed
responses; while some wanted to receive all findings, regardless of actionability, others did not,
particularly when they were for non-treatable conditions or of uncertain significance [161].
However, the interviews also indicated that these participants had an expectation that if they
declined receiving UF now they would be offered the test again at a later stage. Parents have
expressed not wanting to receive UF for their children because they are balancing the benefits
and risks of knowing [69, 75], and small numbers of parents who were worried have raised
concerns regarding insurance discrimination [69, 75], potential emotional/psychological
impacts [69, 75, 104, 105], and anxiety brought on by secondary results [69].
Overall, there did not appear to be a difference between views of participants who were
asked about hypothetical desires for UF and those who were actually deciding to receive these
types of findings. However, a study of 155 individuals offered non-medically actionable SF as a
second-tier test indicated that a lower proportion of participants actually requested to receive
one or more categories (32%) compared to their decision immediately after their initial diag-
nostic disclosure consultation (76%) [105]. Another study of 223 participants of research stud-
ies using exome sequencing showed that preference for UF dropped from 76% at baseline to
65% after pre-test counseling, suggesting that receiving information and deliberation during
the counseling process may change preferences for UF [87].
Biobank setting. No studies explored participants’ preferences for returning UF or SF in
the biobank setting.
2.2 Patients’ (and parents of patients’) preferences for receiving UF or SF
Clinical research setting. Only two studies explored parents’ preferences for receiving UF
for their children [95]. In interviews with parents of children affected by rare diseases, all 15
participants felt that knowing and receiving UF was empowering [95]. Parents also discuss
wanting to be more aware of clinical risks for their child, to take responsibility for their child’s
health, and to allow them to plan (e.g., through proactive financial and health measures) and
support their child [95]. However, parents also mention that they want their child’s results
because they have a right to know them and in order to exercise control over information that
is relevant to their child with the goal of improving care [95]. Parents also want to know their
child’s carrier status so they can prepare their children for the future [95]. A Dutch study con-
ducted 673 surveys and 146 interviews with patients [90]. They found that participants wanted
to receive UF for curable (92%) and incurable conditions (76%), and also where the risk of
developing the condition was high (84%) and low (79%) [90].
Biobank setting. No studies explored patients’ or parents’ preferences for returning UF
or SF in the biobank setting.
2.3 Publics’ preferences for receiving UF or SF
Generally, members of the public expressed either substantial interest in receiving UF or
strong beliefs that UF should be made available to research participants (or their parents) if
they want to receive them [13, 62, 102, 121, 124, 162]. Interviews and focus groups with Afri-
can Americans suggested they felt that professionals are obligated to disclose UF, even if may
cause anxiety for the patient [102]. However, a study which included 1,623 blood donors
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indicated that although 91% said UF should be made available to participants, they were will-
ing to forego receiving UF if returning these findings might compromise the research [13].
Respondents highlighted personal utility [102] and determining how to help their child as rea-
sons for wanting to receive UF [61].
However, some members of the public showed less interest in receiving UF. In a study of
4659 adult Americans, some questioned whether variants predisposing children to late onset
conditions should be returned [62]. This was based on the idea that it may “do more harm
than good” to return inconclusive or non-actionable findings and publics felt that parents
should have the option to opt out of this information. Similarly, a study of 800 Australians
showed that although most participants wanted to receive some UF, less wanted to receive all
types of UF [121]. Two studies suggested that researchers should not actively search for these
findings, as was also expressed by participants [13, 124].
2.4 Health professionals’ views on returning UF or SF
Only three studies have assessed health professionals’ views and experiences returning UF or
SF to participants [163, 164]. In one study, which interviewed 21 genetic and non-genetic clini-
cians returning results of GS as part of the NIH funded Clinical Sequencing Exploratory
Research (CSER), the clinicians stated that in many cases patient-participants were disap-
pointed when no SF were identified and excited when they were. However, this was not always
the case and some were surprised by the identification of SF and unclear about what they
meant for their health risks [164]. In contrast, interviews with 19 professionals, which included
medical doctors, and genetic counselors presented a more cautious approach to both screening
for and returning SF [163]. This was based on a view that the current evidence was lacking and
also a concern about limited availability of resources. Similarly, a study which included 533
genetic health professionals and 843 non-genetic health professionals showed that genetic
health professionals were five times more likely than the public to think that UF should not be
returned and three times more likely than the public to think that genomic researchers should
not actively search for SF irrelevant to their research [124].
2.5 Researchers’ views on returning UF or SF
To date, most of the studies assessing researchers views of returning UF are hypothetical with
few researchers having experience of actually returning UF [165, 166]. Some articles included
perspectives of those who had and had not returned UF/SF. For example, in a study of 198
investigators whose research focus was human disease gene identification, only 16.7% had
returned UF, although 28.8% said they planned to disclose UF in future research studies and
20.2% said they planned to disclose to previous participants [167]. Likewise, in another study,
12% of 234 surveyed researchers had returned UF with another 28% intending to do so [168].
It was not always possible to establish how many of the respondents had experience returning
UF/SF. This was the case in a study of 44 researchers presented with a vignette about identify-
ing a UF which has an increased risk for colorectal cancer, 38 of whom (86%) said that they
would disclose UF [169]. Interestingly, genomics researchers (6/34, 18%) were significantly
less likely than medical geneticists to report a feeling of responsibility to examine the data for
incidental clinically relevant UF (15/26, 57%) [134]. However, if UF are identified 68% (50/74)
felt participants have a strong right to receive them [134]. In a study of 166 stakeholders,
which included 19 genetic researchers and 33 clinical/laboratory geneticists, professional
stakeholders seemed more cautious about the extent that UF should be disclosed to parents
than members of the public, especially if there is uncertainty related to the findings [162].
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Overall, there were very high levels of agreement that participants should be given the
option of deciding whether they wish to receive UF [134, 167, 168] with some studies showing
consensus [170], or near consensus on this point [171]. In a study of 20 basic researchers and
clinical oncology researchers in the Quebec/Ontario adult cancer research community, partici-
pants stated that they felt a moral duty to identify and communicate UF, even if they were not
discussed when participants provided consent [170]. Several studies explored researchers’ rea-
sons for returning UF [148, 165, 168–170]. Researchers raised concepts including UF provid-
ing benefit to participants (e.g. for their health or more broadly) [165, 169], minimizing harm
[169], such as by avoiding participants’ potential anger at developing a condition they were
not informed about [170], and respecting participants’ desires for information [165].
Researchers also discussed participants’ rights to receive UF and having a moral obligation to
return information that could be lifesaving [168].
However, some researchers have stated that they were unsure and conflicted on the issue,
attempting to balance the pros and cons of returning UF [168]. Researchers have expressed
concerns that the research infrastructure and study design to confirm or return UF are gener-
ally lacking [147, 170]. More specifically, they hold concerns about the quality of the test, the
risk for false positive results, and the predictability, reliability and validity of the findings [148,
170]. Of 198 researchers surveyed, many rated return of UF as a moderate (66%) or signifi-
cant/heavy (38.8%) burden [167].
Regarding views on criteria for returning UF, actionability of the findings was highlighted
as a prerequisite and researchers flagged a need for clinical validation and presence of treat-
ment options associated with the finding [170]. Similarly, 95% of 234 surveyed researchers
said that highly penetrant and clinically actionable UF should be returned, although 15% said
that researchers should return all UF [168], with high quality of information and clinical utility
also being listed as main factors by others [169]. Another study showed that researchers
favoured a case-by-case determination of whether or not to return UF [166].
Researchers reasons for not returning UF include the uncertain clinical utility of the find-
ings [165], a lack of expertise in identifying UF [168], concerns that that participants will mis-
understand results [165] and that UF might have negative emotional impacts on participants if
not returned in a supportive manner [165, 168, 170]. Practical considerations were discussed,
such as the costs and time constraints associated with returning UF, a lack of guidelines and
resources on the issue, being ill-equipped to handle the data analysis and delivery of UF [170],
and a need to ensure access to trained clinicians [165]. They also raised concerns relating the
potential for loss of confidentiality [165] and issues relating to difficulties with insurance
[170]. Researchers also suggested distinct goals between the clinical setting and research,
which aims to generate new knowledge [166].
2.6 Institutional Review Boards’ views on returning UF or SF
Five studies, four of which were based in North America, have shown that IRBs have varying
degrees of experience with assessing protocols that discuss return of unsolicited findings [147,
150, 152, 166, 172]. Two studies indicated that, at the time of study, very few of their respon-
dents had actual experience with unsolicited findings [150, 166], and another study of Cana-
dian IRB members, IRB coordinators, and IRB chairs showed that 40% (24/60) had experience
in evaluating protocols that involved the communication of UF [152]. An Indian interview-
based study of 21 ethics committee members highlighted that most had encountered the possi-
bility of UF in their reviews of research protocols and were unsure how to deal with these situ-
ations [147]. However, a large study of 796 IRB members and other IRB professionals reported
that 74% had experience dealing with genetic UF [172]. Of these, the majority (65%) felt that
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there was “sometimes” an obligation to disclose UF with only a small proportion (13%) saying
there was “always” an obligation to disclose UF [172]. Their rationale behind disclosure of UF
was because they felt there was a duty to warn participants if they are in significant, imminent
danger, because it respects the autonomy of participants, and because of the potential benefit
[172]. However, 96% indicated that it is either definitely or probably acceptable for a partici-
pant to elect not to receive any UF [172].
A study of 34 Chairs of IRBs in institutions in which Genome Wide Association Studies
(GWAS) had been conducted suggested that IRB chairs view genetic UF as different to other
types of findings due to the uncertainty relating to both the significance and potential of the
findings, as well as the broader implications for family members and potential for social impli-
cations, such as discrimination and stigma [173].
When determining whether UF should or should not be returned from research studies,
consideration of risks to participants was highlighted as an important factor, as were current
regulations [152, 166]. IRB chairs preferred procedures for disclosure to be decided upon prior
to researchers seeking ethics approval, rather than on a case-by-case basis [166]. Factors such
as the additional time and effort required for the researcher to disclose UF [172], a lack of
resources [172], and disclosure based on the concept of reciprocity [152] were not viewed as
important considerations in determining whether UF should be returned. Although a study
suggested that the financial cost of communicating UF was not a strong reason for not com-
municating these findings, they identified that IRB members were more likely to consider the
financial costs if they were more experienced in reviewing genetic/genomic protocols, particu-
larly if they involved returning UF [152].
3. Experiences with receiving or returning results
A summary of the experiences of participants, patients and public with receiving results is pro-
vided in Table 6. A summary of participants’, patients’ and publics’ perceptions of utility and
behavioural change is provided in Table 7.
3.1 Participants’ reactions to receiving results
Clinical research setting. Many of the studies assessing participants’ responses and out-
comes of receiving IRR were quite positive. Studies have shown high [87] or moderate to high
satisfaction with decisions to receive results [8, 174]. Ten studies that asked participants
whether they regretted participating in the research showed that either most [175, 176] or all
of the participant reported little [155] or no regret at taking part and receiving IRR [79, 87,
174, 177–181]. In fact, a study of 202 participants–comprised of roughly half healthy adults
and half patients with either hypertrophic cardiomyopathy or dilated cardiomyopathy–who
received health information based on either family history alone or family history and genomic
sequencing information, found that those who received genomic results reported lower aver-
age levels of decisional regret [182]. In addition, a study of 152 adults randomized to be offered
SF found that participants who chose not to receive SF were more likely to feel regret than
those who chose to learn SF [155]. However, one study of 117 adult participants of a ClinSeq
Study in whom a variant associated with coronary artery disease risk was identified and
returned showed that decision regret was significantly different between participant groups;
those with VUS-low results (meaning that the evidence relating to the pathogenicity of these
variants is approaching ‘likely benign’) reported greater regret than those with VUS-high
results (where the evidence was approaching ‘likely pathogenic’) [183]. This suggests that
uncertainty resulting from lack of information about the variants identified increased
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Table 6. Summary of experiences of participants, patients and public with receiving results.
Experiences of receiving IRR Participants Patients Publics
Moderate to high satisfaction [8, 87, 174, 184]




High rates of wellbeing [8]
Positive emotions [187]
Low levels of uncertainty [188] [189]
Low levels of negative emotions [159, 188]
Low levels of concern [190, 191]
No or low levels of distress [83, 87, 188, 192] [189]
No impact on anxiety or depression [31, 180, 193]
No impact of self-rated health [176]
No adverse impact on quality of life [175, 176]
No psychological harm [83] [194]
Low perceived harm [181]
No adverse impact on wellbeing [193]
No adverse effects on emotions [176]
No or little regret [79, 87, 155, 174, 177–181, 188] [189]
Lower regret if chose to receive IRR [155, 182]
No fatalistic reactions [195]
Some distress or worry [80, 176, 180, 186, 196, 197]
Some anxiety and depression [175, 179, 198–201]
Lower positive feelings [176]
Disappointment [175]
Concern [83, 175, 199]
Guilt [180, 202]
Indifference [175]
Uncertainty and confusion [175, 176, 180, 182, 203]
Increased perception of risk [80, 83] [204]
Desire for more results [174, 175]
https://doi.org/10.1371/journal.pone.0258646.t006
Table 7. Summary of participants’, patients’ and publics’ perceptions of utility and behavioral change.
Perceptions of utility Participants Patients Publics
Value in having an answer or a name [174, 177]
Potential for surveillance, early disease detection, access to
treatment
[9, 87, 153, 177, 182, 198]




Empowerment and greater sense of control [87, 174]
Benefit to science [177]
Behavior change
Some behavior change [9, 31, 100, 186, 200, 205]
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decisional regret [183]. Returning results to parents led to greater satisfaction as did offering a
choice about which results to receive [184].
Most participants reported either positive or neutral impacts of receiving results, both
when they were related to the study and also for UF/SF [9, 65, 79, 153, 157, 159, 174–176, 178,
179, 181, 182, 185, 187, 190, 191, 195]. A study of 17 research participants and family members
who received UF showed that most (16/17) found the process mainly positive or useful and
were thankful for being told they have the disease, both for their own wellbeing and also
because it provides valuable knowledge for their children [153]. Another study of 31 adult par-
ticipants in the ClinSeq cohort found that participants expressed relief that the result did not
suggest a more serious condition, reassurance about their current healthcare, and satisfaction
that they were able to access surveillance [9]. Most participants in the study (27/31) reported
that their feelings about their result became more positive over time. This finding was sup-
ported by another study of 133 individuals who received testing for the CDKN2A gene for mel-
anoma, where both carriers and noncarriers reported greater levels of hopefulness 6 months
after disclosure than beforehand [176].
Similarly, although reports from 223 participants suggest modest impact from receiving IRR,
they too expressed relief, either that an increased risk was not identified, or that the results were
not indicative of more severe health consequences [87]. Interviews with 12 individuals from the
Integrated Personal Omics Profiling project showed that while the majority of participants were
underwhelmed by their results, several expressed feelings of validation or closure when their
results could play a role in an existing health condition [79]. Other studies have also identified
relief [79, 176, 185], gratitude [176], feelings of greater control [174], and that receiving results
was valuable [174] and would influence medical treatment [182]. Additionally, assessment of 10
scientists and researchers who received results from genomic sequencing showed no apparent
adverse events or reactions from disclosure of SF; variants were found in 9/10 participants
[208]. There was also no evidence of adverse effects on self-rated health, quality of life, or emo-
tional experience among either carriers or noncarriers tested for CDKN2A melanoma risk 6
months after disclosure [176].
However, some studies identified negative or mixed emotions from receiving IRR [174–
178, 182, 196, 202]. A study of 10 women who had participated in the Australian Ovarian Can-
cer Study to determine prevalence of BRCA1 and BRCA2 mutations and 15 next of kin showed
that interviewees had mixed responses to receiving feedback; many of the relatives were ini-
tially distressed, particularly if they had not realised their mother had participated in the study
[196]. Another study of 3 adults diagnosed with invasive breast cancer in whom BRCA1 or
BRCA2 mutations were identified and then returned also showed mixed reactions, including
some guilt, although one year after confirmatory testing all of the interviewees considered that
there were more advantages than disadvantages to receiving the information [202]. Individuals
identified to be carriers of the at-risk CDKN2A variant for melanoma (n = 15) reported higher
distress, higher uncertainty, and lower positive feelings immediately after receiving their result
than noncarriers [176].
A few participants in the study of 35 individuals who underwent whole genome sequencing
expressed negative reactions, such as concern, disappointment, indifference, confusion, and a
desire for more results [175]. Similarly, 54% of 543 healthy participants from within four proj-
ects of the PeopleSeq Consortium were disappointed that their results did not tell them more
information [174]. Participants from the study of 202 healthy adults and patients with either
hypertrophic cardiomyopathy or dilated cardiomyopathy who had received genetic results were
more likely to feel they had received a lot, or even too much information compared to those
who received family history information alone [182]. They were also generally less satisfied with
their understanding and felt lower levels of confidence in their ability to explain results to family
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members [182]. Interestingly, a study of 24 individuals who participated in a genotype driven
study on cystic fibrosis (9 participants with CF and 15 from a biobank cohort) showed that bio-
bank participants were usually less sure than CF patients about why they had been selected and
how they should conceive of themselves and their health, suggesting that being recruited based
in genotype may create uncertainty for participants [203].
Some studies have suggested aspects across a range of different domains of utility that par-
ticipants feel they gained through return of IRR. Participants appreciate the potential for sur-
veillance and the ability to seek targeted medical care, which can lead to early detection and/or
disease prevention, both for themselves and also their family members [9, 87, 198]. They also
express empowerment from the knowledge of the genetic cause of their condition or, in the
case of other information, such as carrier status or pharmacogenetic information, highlighted
the importance of sharing this with family [87]. A study of 18 volunteers who agreed to have a
genetic test for the FTO gene related to obesity believed that knowing their result would moti-
vate them to try to control their weight in the future [195]. Another study showed parents val-
ued having an answer and being able to put a name to their child’s condition, as well as the
ability to predict and manage their child’s future health [177]. They also discussed the benefits
of reproductive planning for any family member and being able to help science [177]. Focus
groups with 24 members of the Hmong community in the USA who received pharmacogenetic
results showed that as well providing benefit through allowing for changes in their medication,
participants also identified that returning results benefited the broader community [187].
In relation to psychological outcomes, several studies have shown low levels of distress [87,
192], low levels of concern [190, 191], low levels of negative emotions [159], and high rates of
wellbeing from receiving IRR [8]. In Sanderson et al’s 35 healthy adult participants, no changes
were detected in anxiety, depression or quality of life in response to receiving results between
baseline and later measures [175]. Similarly, a project that tested 19 adult participants with a
personal history of melanoma for genetic susceptibility to the condition showed no significant
psychological harm from disclosure [83]. Event-specific distress was also low in these partici-
pants. Despite this, mutation carriers reported greater subjective concern about test results
and also perceived their risks for another melanoma to be higher than non-carriers. In addi-
tion, a study of 13 adult family members of deceased men with early-onset prostate cancer
who had participated in a study and who had been found to have a BRCA2 mutation showed
that some participants experienced distress and anxiety, although this was resolved through
genetic counseling [198].
A number of studies have explored psychological outcomes in response to receiving APOE
results in various iterations of the REVEAL study [80, 185, 192, 193, 199, 201, 209, 210]. These
studies have explored responses to receiving versus not receiving genetic risk results, receiving
deterministic versus susceptibility information, and also to different ways of disclosing results.
The initial publication from this study, reporting on 162 adults who had a parent with Alzhei-
mer’s Disease (AD) suggested genotype disclosure did not adversely affect participants’ psy-
chological wellbeing, or lead to anxiety or depression with group means of these measures
rating well below clinical cut off scores [193]. A subsequent study comparing disclosure of
results of susceptibility testing within the REVEAL study (n = 101) versus deterministic testing
in another study by University of Washington (n = 22) showed similar low levels of distress in
both cohorts [192]. Another study where 162 participants were randomized into disclosure
(n = 111) and non-disclosure (n = 51) arms showed no significant differences in distress
between the two arms, yet did report differences between APOE e4+ and e4- at 6 weeks, 6
months and 12 months [80]. Although participants reported higher likelihood of perceived
risk and an overall negative effect of disclosure in the APOE e4+ group, they were no less likely
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to say they would retest than the APOE e4- group and attributed their psychological state to
factors other than the results [80].
A study comparing extended, in-person APOE result disclosure with a condensed disclosure
process suggested that 45% of their 269 participants reported an increase in depressive symp-
toms although only 9% were above the clinical cut off at 6 months [199]. Reports of increased
depression at 12 months were associated with lower causal attribution to genetics and higher
perceived risk of developing AD and level of concern decreased significantly more in those
who received e4- results than e4+ [199]. In a study that compared outcomes from disclosing
risks for AD alone with AD plus Coronary Artery Disease (CAD), 24% of participants reported
moderate anxiety, depression, or test-related distress at one or more follow-up time points with
no difference between the AD-only and AD+CAD groups [210]. In this study, mean distress
scores and anxiety were greater in participants that received e4+ results but only for those in
the AD only group. Another study that included 111 participants with mild cognitive
impairment who were randomized into disclosure (n = 75) and non-disclosure arms (n = 39),
showed that mean anxiety and depression scores in both arms were below clinical cut-offs at all
time points [209]. Those in the disclosure arm who were e4- had lower test-related distress and
greater positive impact than those who were e4+ [209]. Interestingly, individual scores for anxi-
ety, depression, and hopelessness were more likely to be above clinical cut-offs, indicating
cause for concern, if they were in the non-disclosure than the disclosure group [209].
Several studies have also assessed behavioral change in response to IRR. Most of these stud-
ies have shown little to no behavioral change [8, 79, 83, 87, 198, 206, 207] nor intentions to
change behavior [183]. For example, disclosure of IRR in participants of the melanoma study
had very little impact on motivating participants to adopt more prevention behaviors, such as
wearing long sleeve shirts or pants when exposed to the sun or performing self-examinations,
even in those who were identified to carry pathogenic variants in CDKN2A [83]. Family mem-
bers of men with early-onset prostate cancer were less likely to engage with information and
have screening if they were sceptical about the relative that informed them of their risk, if they
were younger, and if they were afraid of cancer [198]. Although a study of 107 men and
women from families with a known MMR gene mutation (which increases cancer risk)
showed a slight increase in screening measures among participants, irrespective of test result,
this was not significant [8].
Yet, participants do appear to take some steps based on receiving results. More participants
in the MMR study who received an IRR indicating a pathogenic mutation took further steps to
discuss screening than those who were negative [8]. In a study of 68 individuals without car-
diomyopathy who had received VUS for a cardiomyopathy gene, 15 went on to engage in
health-related behavior change: nine had cardiac testing (for some of whom there were clinical
indications) and 12 made lifestyle changes [205]. The study of healthy individuals who were
randomized to receive testing for either AD+CAD or AD alone showed that 57% reported
changing at least one health behavior at 12 months in response to genetic risk disclosure [210].
Although this was more likely in the AD+CAD group than AD alone, this finding was inde-
pendent of genotype [210]. In the ClinSeq cohort, 25/31 participants sought information
about the variant and its associated health condition online after receiving their result [9]. Yet,
of the seven healthy participants that received likely pathogenic or pathogenic rare disease
associations, only 2 had acted on their results [175].
3.1 Participants’ reactions to receiving results (continued)
Biobank setting. Four studies explored the outcomes from returning IRR to biobank par-
ticipants [204]. Surveys were conducted with 55 participants who were part of a cohort of
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people with pancreatic cancer who were tested for variants in CDKN2A for melanoma risk,
explored the outcomes from returning SSR to biobank participants [204]. They found that
CDKN2A carriers worried more about developing pancreatic cancer than non-carriers at pre-
disclosure, immediately post disclosure, and also 6 months later [204]. In addition, more carri-
ers thought they had a higher than average chance of developing melanoma at predisclosure
and 6 months post-disclosure than non-carriers, which remained significant after excluding
those with history of melanoma [204]. An Estonian study that returned pathogenic variants in
BRCA1/2 genes to 22 biobanks participants found they generally felt calm and relaxed follow-
ing genetic counselling, although a small number of participants reported feeling tense or wor-
ried [197]. A second Estonian study, in which 16p11.2 CNVs were reported back to 5 carriers,
showed most were relieved and were coping with the information, although two said they
were slightly worried [186]. In addition, surveys with ten thoracic aortic dissection biobank
participants in the USA who received pathogenic variants showed low levels of psychological
distress, negative feelings, uncertainty and privacy concerns [188].
In the two studies that explored behavior change in response to results was generally poor
[186, 204]. Most participants in the CDKN2A did not have their results confirmed by a clinical
laboratory, less than half had enacted pancreatic checks, and less than a third had had a skin
test by 6 months follow up [204]. In the Estonian study that reported UF, two respondents vis-
ited a genetic specialist and this led to a treatment modification for one participant [186].
3.2 Patients’ (and parents of patients’) reactions to receiving results
Only two studies have examined the outcomes from returning results to patients [43, 189]. A
study of 107 BRCA1/2-negative women with early-onset breast cancer, multiple primary can-
cers, or a family history of breast cancer showed that knowledge increased significantly after
predisclosure counseling and receipt of results, including knowledge in those who received
negative results or VUS [43]. Psychological assessments indicated that general anxiety and
intrusive cancer-specific distress declined significantly for participants who received positive
and negative results, as did depression [43]. However, cancer worry only declined significantly
for those with a negative result [43]. An Australian study that recruited 133 participants from
the Cancer Council registry, which included cancer patients, their family and friends, and
members of the general public, showed that 95% of participants reported ‘never’ feeling regret
about receiving their risk information [189]. Although the mean total scores of distress and
uncertainty differed significantly depending on the risk category–the group at high-risk
reported the highest mean Multidimensional Impact of Cancer Risk Assessment (MICRA)
scores–scores were relatively low overall [189].
3.3 Publics’ reactions to receiving results
Only two studies have investigated outcomes from returning results to members of the public.
The first is the Australian study of 133 participants from the Cancer Council registry described
above, which also included cancer patients and their family and friends [189]. The second
reported on 280 cognitive healthy, Chinese English-speaking participants in Singapore that
had APOE genotype testing [194]. Assessment using the Beck Anxiety Inventory (BAI) and
Centre for Epidemiologic Studies Depression scale (CESD) showed no evidence of APOE
genotype disclosure resulting in adverse psychological outcomes [194]. In addition, they did
not identify any significant associations between APOE e4 genotype and behavior changes,
such as diet, supplement consumption, and physical or cognitive activity [194].
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3.4 Health professionals’ experiences returning results
Only two studies assessed health professionals’ experiences with returning individual research
results to participants. One study conducted surveys (n = 21) and interviews (n = 22) with
health professionals who had been involved with the eMERGE study [178]. While most partici-
pants thought sequencing results were important to participant’s health, nearly half held con-
cerns about inflicting harm through unnecessary investigations [178]. Many lacked confidence
in their ability to explain the results to patients (72%) and to answer any questions they might
have (78%). Interviews with 21 genetic and non-genetic clinicians suggested variable reactions
by patients to receiving individual research results [164]. While some patients showed enthusi-
asm and relief at receiving IRR, others expressed confusion and disappointment; this differ-
ence depended on the results they received, their health status, and also their existing
healthcare experiences. While some patient-participants felt it was good to have an answer, it
could also be challenging to receive a result when the genetic basis indicates that the condition
is progressive or worse than anticipated. This may be exacerbated when the condition is rare,
meaning that access to information and support groups is limited. Responses to negative
results (i.e., when no answer is identified) also varied from disappointment to relief, depending
on the expectations that patients held for a result being identified. Finally, in relation to
patients’ reactions to receiving VUS, health professionals described difficulties getting patient-
participants to understand the results and overinterpretation of the significance of the variant
in some cases. Similar to receiving a result that identified the genetic basis of their condition,
patients could have either positive or neutral reactions, depending on their diagnostic odyssey.
Discussion
To our knowledge, this is the first systematic review to focus exclusively on stakeholder per-
spectives on return of results from genomic research. Overall, interest in receiving SRR was
high across all stakeholder groups, particularly in the biobank setting. Although interest in
receiving UF/SF was also quite high across all stakeholders, some members of the public did
indicate less interest in receiving such results, questioning whether returning inconclusive or
non-actionable findings, such as variants predisposing children to late onset conditions, might
do more harm than good [62].
Interest in results was highest both when they were health related and when they were what
could be considered to be ‘actionable’, i.e., the information could lead to some form of preven-
tion or treatment [3, 4, 10, 33, 34, 39, 41, 42, 112, 155]. The concept of ‘actionability’ is often
used to suggest that a result has clinical utility, i.e., that the result has the potential to influence
patient management [211]. However, the exact meaning of this remains highly contested,
despite considerable attention in the literature [212–214], making it difficult for researchers to
determine what types of results might be appropriate to return, and when. We suggest that
examining the reasons that patients and participants wish to receive results may provide us
with another lens for assessing which results to return. Studies showed a wide range of reasons
for wanting study-specific results and UF. Many of the reasons for desiring IRR related to the
potential for individual health benefits, such as having greater perceived certainty about their
personal level of risk [8, 83], or that of their child [95], determining whether they require
screening [8] or medical interventions [42], health-related planning [87], and being able to pre-
pare for their child’s future heath needs [11]. However, some express desires to be mentally pre-
pared and to be proactive in planning their finances, including insurance and housing [42, 95].
Others go beyond clinical utility and into the realms of what could be considered ‘personal
utility’. Participants describe feelings of parental responsibility or moral obligation, a perceived
right to know their child’s results, and desires to inform their children of their results [11, 75,
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83, 95]. Finally, some just want to know results out of curiosity [48, 83, 87], or a need for con-
trol [11]. A study by Kohler et al used a Delphi method with participants of the ClinSeq cohort
to delineate 14 types of personal utility [215]. These include ‘mental preparation’, ‘ability for
future planning’, ‘feelings of responsibility’, ‘to enhance coping’, and ‘curiosity’, which suc-
cinctly encompass the reasons identified by our analysis.
Yet, it is important to distinguish personal utility from ‘perceived utility’, where those
undergoing testing may believe that there might be some benefit from receiving the result
when, in fact, there is not because the information is not valid or reliable [216]. As such,
whether a result has personal utility or merely perceived utility can only be determined on a
result-by-result basis [216]. While the question remains as to whether results that have bona
fide personal utility should be returned in the context of genomic research (with the resourcing
issues this entails), these results suggest that grouping results based on actionability (depending
on how it is defined) may be less helpful than considering a broader concept of utility. Whether
the IRR are study-specific or beyond the research question may also need to be considered.
It was striking that the position from which IRR are judged (i.e., positionality) and how IRR
impact one’s particular circumstances (i.e., situatedness) [217], both strongly shaped the per-
spectives of stakeholders. While members of the public also desire results to improve both cur-
rent and future health [56, 91, 93], there is some evidence that they are more interested in
receiving information about non-medical traits and variants of uncertain significance than
patients or participants [91]. Their rationale that these types of results might be meaningful
later on or may reveal something about them or their family may reflect the fact that they are
representing a ‘lay’ perspective, which is in contrast to those who are participating in genetic
research because of their disease status. In addition, although general willingness to receive
IRR was high, several studies showed that some members of the general public were concerned
about receiving results because of its implications for insurance discrimination and the poten-
tial impact of the findings on their mental health [56, 59, 91, 93]. It is interesting that these
concerns did not arise in studies of patients or participants, which may again be due to the fact
that they (or their child) are already affected with a genetic condition and therefore may be
more focused on receiving information that may promote their current health than concerns
for their future health [218].
It is also important to highlight the ways in which both the framing of questions and the
opportunity for deliberation may influence interest in receiving IRR. Our review identified
instances where the findings of qualitative studies with participants or members of the public
showed lower support for receiving IRR than those that were quantitative in nature [91]. In
addition, several studies showed that while interest in receiving IRR remains relatively high,
there was a decrease in interest after either counselling or some form of educational interven-
tion [87, 105, 114]. Furthermore, a recent study has shown that proportions of participants
who were informed that a new genomic finding had been identified chose not to proceed with
variant confirmation and detailed disclosure [219, 220]. These findings support the need for
education and support for participants during the consent process to ensure their decision is
informed. More research into the ways in which this can be achieved is required.
Importantly, our analysis shows that many of the studies assessing participants’ actual expe-
riences of receiving individuals research results were quite positive. A proportion of these stud-
ies spoke to different domains of utility that participants felt they gained through return of
results, including the potential for surveillance and the ability to seek targeted medical care,
which in turn could lead to early detection and/or disease prevention both for themselves and
family members [9, 87, 198]. They also expressed empowerment from the knowledge of the
genetic cause of their condition [87]. Several studies assessing psychological outcomes of actual
experiences around returning results (both qualitative and quantitative in nature) showed low
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levels of negative emotions [159], low levels of distress [87], no significant psychological harm
[83], no fatalistic reactions [195], and high rates of wellbeing from the receipt of individual
results [8]. One study also found that disclosure of results may reduce anxiety, depression and
feelings of hopelessness, suggesting that uncertainty may be more harmless than disclosure
[209]. Although some studies identified negative or mixed emotions from returning results
[174–178, 182, 196, 202], importantly, one study in which some participants experienced dis-
tress and anxiety, suggested that this resolved with genetic counseling [198]. We should note
that we did not assess the processes by which IRR were returned within this review and the
level of support provided in the return process are likely to impact on how well IRR are
received, as raised as a concern in several studies [165, 168, 170].
In contrast to views of participants, patients and members of the publics, healthcare profes-
sionals, researchers, and members of IRBs seemed overall to be less positive and more cautious
about returning results [44, 124], though there were fewer studies that assessed the perspectives
of these stakeholders. They were generally more supportive of returning results that are reliable
and have clinical relevance and utility, rather than results where the significance or utility of
the findings is uncertain [76, 134, 135, 138]. In contrast to potential recipients of genomic
results, the key concerns expressed by professionals mainly related to the uncertainty of the
results being returned and the blurring of lines between research and clinical care [139, 140].
Concerns about results instilling fear in participants were also raised [145]. The fact that pro-
fessionals raise different concerns to potential recipients of results of genomic research is per-
haps unsurprising given the more cautious approach that genetic health professionals take to
providing testing in other contexts [221, 222]. It may also be reflective of the role they play in
determining which results should be returned, particularly if they are involved in the analysis/
interpretation process. It should also be noted that ability and even willingness to return results
by researchers and health professionals in certain studies may be dictated by country-specific
regulations. While it may be unsurprising that parents care about the impact on their child’s
health or that researchers are concerned about the resource-based of returning findings, the
importance of these contexts for shaping return of IRR cannot be understated. In particular,
the finding that IRB members who are not experienced in reviewing genomic protocols were
less likely to consider the financial costs of returning IRR, highlights how critical it is to involve
those who have experience in this area in protocol development [152].
Only two studies focused on actual experiences of health professionals returning IRR [164,
178], and no studies focused on experiences of researchers or IRBs, although several studies
included proportions of stakeholders that had done so. The study by Wynn et al. reported simi-
larly mixed responses by participants to receiving results from genomic research, which were
often dependent on the type of result they received, their health status, and their previous expe-
riences in the healthcare system, including the duration of their diagnostic odyssey [164]. Fur-
ther research could be undertaken to explore professionals’ experiences with returning IRR in
order to help develop the most appropriate infrastructure and resources required to return IRR.
This review has certain limitations. The majority of relevant studies were conducted in the
USA, United Kingdom or Canada and were comprised predominantly of White participants.
Participant views are likely to be heavily influenced by what is standard practice in the clinical
setting and therefore dependent on the healthcare system, and availability of health insurance,
in their region. As such, the perspectives identified cannot necessarily be generalized to other
cultural groups or national healthcare contexts and should be used with caution in the devel-
opment of regulation for unrepresented groups. The vast majority of studies are from the USA
which is important given they are currently the only nation to have guidelines that endorse
actively searching for SF in the clinical setting [223]. Several studies with different types of
stakeholders did not present separate findings for each stakeholder group. Where this was the
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case, the results of the study were reported within the most prominent stakeholder group or
included in the ‘mixed professional’ category where there was no prominent stakeholder
group. At times this made it difficult to determine whether studies were discussing just study-
specific results or all IRR, as some papers appeared to conflate the two. In such circumstances,
categorisation was led by the context in which the stakeholders were being asked the question.
We also acknowledge that our quality assessment approach did not prioritize inclusion of
studies based on study quality. Finally, some of the studies included are older and as such
information about ‘current’ practices regarding return of results–particularly in relation to
researchers, health professionals and IRBs–are likely to have evolved considerably.
Conclusion
We have provided overwhelming evidence that, at least for the United States, Canada and some
other countries, there is a high interest in return of results from the stakeholders who either
are, or would be, receiving them. There is also a general willingness to provide such results by
those who would be doing so, although the latter tend to adopt a more cautious stance. While
all results are desired to some degree, those that have the potential to change clinical manage-
ment appear to be more valued. In addition, professional stakeholders appear more willing to
return results that are reliable and clinically relevant. Furthermore, the lack of evidence of
enduring psychological harm from returning results suggests that doing so is appropriate.
As such, we feel it is time to move away from questions about whether individual research
results should be returned and to focus on which types of IRR to return in each context and
how to return them in an ethically appropriate and supportive manner. Gaps remain in our
knowledge of how to achieve this. First, a large proportion of the studies identified gauged
hypothetical views while very few used deliberative methodologies to help participants under-
stand the implications of their decisions regarding return of results. Second, gaining a more
comprehensive understanding of the motivations of different stakeholders will allow for feed-
back of results to be better tailored to the research study and context. To address these two
points, if more research in this field is to be conducted it should involve individuals who are
actually making decisions about receiving IRR and investigating ways in which to best support
this process, both within the scope of existing large-scale projects and biobanks, and also in the
planning of future research endeavours. Third, as three quarters of the papers were based on
studies conducted in the United States and Canada, along with the fact that the limited studies
conducted in other parts of the world suggest some cultural variation, more work will also be
required to accommodate different cultural settings.
To ensure that return of IRR is done well across the board, best practices for the return of
IRR are needed [22]. Clear pathways for return of results are required, as is training for those
returning IRR and those obtaining consent to do so. There also needs to be adequate resources
available to return IRR, including access to genetic counselling and other specialist expertise
when required. We must think as well about the point at which the obligations of researchers
to return IRR cease, particularly as reanalysis and reinterpretation processes become more
automated. Finally, the development of practical guidelines and informative frameworks
adaptable to all settings are needed to support researchers in putting appropriate return of IRR
protocols in place.
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Disclosure: Perceptions of Participants in a Nutrigenetic Study in Finland. Public Health Genomics.
2021; 24(1–2):33–43. https://doi.org/10.1159/000512640 PMID: 33486491
192. Cassidy MR, Roberts JS, Bird TD, Steinbart EJ, Cupples LA, Chen CA, et al. Comparing test-specific
distress of susceptibility versus deterministic genetic testing for Alzheimer’s disease. Alzheimer’s &
Dementia. 2008; 4(6):406–13. https://doi.org/10.1016/j.jalz.2008.04.007 PMID: 19012865
193. Roberts JS, Cupples LA, Relkin NR, Whitehouse PJ, Green RC, Group RS. Genetic risk assessment
for adult children of people with Alzheimer’s disease: the Risk Evaluation and Education for Alzhei-
mer’s Disease (REVEAL) study. Journal of Geriatric Psychiatry and Neurology. 2005; 18(4):250–5.
https://doi.org/10.1177/0891988705281883 PMID: 16306249
194. Sng WT, Yeo SN, Lin BX, Lee TS. Impacts of apolipoprotein e disclosure on healthy Asian older
adults: a cohort study. International Psychogeriatrics. 2019; 31(10):1499–507. https://doi.org/10.
1017/S1041610218002089 PMID: 30894233
195. Meisel S, Wardle J. ‘Battling my biology’: psychological effects of genetic testing for risk of weight
gain. Journal of Genetic Counseling. 2014; 23(2):179–86. https://doi.org/10.1007/s10897-013-9628-9
PMID: 23832708
196. Hallowell N, Alsop K, Gleeson M, Crook A, Plunkett L, Bowtell D, et al. The responses of research par-
ticipants and their next of kin to receiving feedback of genetic test results following participation in the
Australian Ovarian Cancer Study. Genetics in Medicine. 2013; 15(6):458–65. https://doi.org/10.1038/
gim.2012.154 PMID: 23448721
197. Leitsalu L, Palover M, Sikka TT, Reigo A, Kals M, Pärn K, et al. Genotype-first approach to the detec-
tion of hereditary breast and ovarian cancer risk, and effects of risk disclosure to biobank participants.
European journal of human genetics: EJHG. 2021; 29(3):471–81. https://doi.org/10.1038/s41431-
020-00760-2 PMID: 33230308
198. Ormondroyd E, Moynihan C, Watson M, Foster C, Davolls S, Ardern-Jones A, et al. Disclosure of
genetics research results after the death of the patient participant: a qualitative study of the impact on
relatives. Journal of Genetic Counseling. 2007; 16(4):527–38. https://doi.org/10.1007/s10897-007-
9088-1 PMID: 17492498
199. Ashida S, Koehly LM, Roberts JS, Chen CA, Hiraki S, Green RC. The role of disease perceptions and
results sharing in psychological adaptation after genetic susceptibility testing: the REVEAL Study.
European Journal of Human Genetics. 2010; 18(12):1296–301. https://doi.org/10.1038/ejhg.2010.119
PMID: 20664629
200. Christensen KD, Roberts JS, Whitehouse PJ, Royal CDM, Obisesan TO, Cupples LA, et al. Disclosing
Pleiotropic Effects During Genetic Risk Assessment for Alzheimer Disease A Randomized Trial. Annals
of Internal Medicine. 2016; 164(3):155–U48. https://doi.org/10.7326/M15-0187 PMID: 26810768
201. Christensen KD, Uhlmann WR, Roberts JS, Linnenbringer E, Whitehouse PJ, Royal CD, et al. A ran-
domized controlled trial of disclosing genetic risk information for Alzheimer disease via telephone.
Genetics in Medicine. 2018; 20(1):132–41. https://doi.org/10.1038/gim.2017.103 PMID: 28726810
202. Nilsson MP, Emmertz M, Kristoffersson U, Borg Å, Larsson C, Rehn M, et al. Germline mutations in
BRCA1 and BRCA2 incidentally revealed in a biobank research study: experiences from re-contacting
mutation carriers and relatives. Journal of Community Genetics. 2018; 9(3):201–8. https://doi.org/10.
1007/s12687-017-0341-5 PMID: 29082482
203. Michie M, Cadigan RJ, Henderson G, Beskow LM. Am I a control?: Genotype-driven research recruit-
ment and self-understandings of study participants. Genetics in Medicine. 2012; 14(12):983–9. https://
doi.org/10.1038/gim.2012.88 PMID: 22935717
204. Leof ER, Zhu X, Rabe KG, McCormick JB, Petersen GM, Breitkopf CR. Pancreatic cancer and mela-
noma related perceptions and behaviors following disclosure of CDKN2A variant status as a research
result. Genetics in Medicine. 2019; 21(11):2468–77. https://doi.org/10.1038/s41436-019-0517-y
PMID: 30992552
PLOS ONE Systematic review of stakeholder perspectives on return of results
PLOS ONE | https://doi.org/10.1371/journal.pone.0258646 November 8, 2021 70 / 71
205. Miller IM, Lewis KL, Lawal TA, Ng D, Johnston JJ, Biesecker BB, et al. Health behaviors among unaf-
fected participants following receipt of variants of uncertain significance in cardiomyopathy-associated
genes. Genetics in Medicine. 2019; 21(3):748–52. https://doi.org/10.1038/s41436-018-0083-8 PMID:
29997389
206. Chao S, Roberts JS, Marteau TM, Silliman R, Cupples LA, Green RC. Health behavior changes after
genetic risk assessment for Alzheimer disease: The REVEAL Study. Alzheimer Disease and Associ-
ated Disorders. 2008; 22(1):94. https://doi.org/10.1097/WAD.0b013e31815a9dcc PMID: 18317253
207. Hart MR, Biesecker BB, Blout CL, Christensen KD, Amendola LM, Bergstrom KL, et al. Secondary
findings from clinical genomic sequencing: prevalence, patient perspectives, family history assess-
ment, and health-care costs from a multisite study. Genetics in Medicine. 2019; 21(5):1100–10.
https://doi.org/10.1038/s41436-018-0308-x PMID: 30287922
208. Lindor NM, Schahl KA, Johnson KJ, Hunt KS, Mensink KA, Wieben ED, et al. Whole-exome sequenc-
ing of 10 scientists: evaluation of the process and outcomes. Mayo Clinic proceedings. 2015; 90
(10):1327–37. https://doi.org/10.1016/j.mayocp.2015.05.021 PMID: 26434960
209. Christensen KD, Karlawish J, Roberts JS, Uhlmann WR, Harkins K, Wood EM, et al. Disclosing
genetic risk for Alzheimer’s dementia to individuals with mild cognitive impairment. Alzheimer’s &
Dementia: Translational Research & Clinical Interventions. 2020; 6(1):e12002. https://doi.org/10.
1002/trc2.12002 PMID: 32211507
210. Christensen KD, Roberts JS, Whitehouse PJ, Royal CD, Obisesan TO, Cupples LA, et al. Disclosing
pleiotropic effects during genetic risk assessment for Alzheimer disease: a randomized trial. Annals of
Internal Medicine. 2016; 164(3):155–63. https://doi.org/10.7326/M15-0187 PMID: 26810768
211. Burke W, Atkins D, Gwinn M, Guttmacher A, Haddow J, Lau J, et al. Genetic test evaluation: informa-
tion needs of clinicians, policy makers, and the public. Am J Epidemiol. 2002; 156(4):311–8. https://
doi.org/10.1093/aje/kwf055 PMID: 12181100
212. Dyke SOM, Saulnier KM, Dupras C, Webster AP, Maschke K, Rothstein M, et al. Points-to-consider
on the return of results in epigenetic research. Genome medicine. 2019; 11(1):31. https://doi.org/10.
1186/s13073-019-0646-6 PMID: 31122281
213. Richer J, Laberge A-M. Secondary findings from next-generation sequencing: what does actionable in
childhood really mean? Genetics in Medicine. 2019; 21(1):124–32. https://doi.org/10.1038/s41436-
018-0034-4 PMID: 29875419
214. Moret C, Mauron A, Fokstuen S, Makrythanasis P, Hurst SA. Defining categories of actionability for
secondary findings in next-generation sequencing. Journal of Medical Ethics. 2017; 43(5):346–9.
https://doi.org/10.1136/medethics-2016-103677 PMID: 28039284
215. Kohler JN, Turbitt E, Lewis KL, Wilfond BS, Jamal L, Peay HL, et al. Defining personal utility in geno-
mics: A Delphi study. Clin Genet. 2017; 92(3):290–7. https://doi.org/10.1111/cge.12998 PMID:
28218387
216. Bunnik EM, Janssens AC, Schermer MH. Personal utility in genomic testing: is there such a thing?
Journal of Medical Ethics. 2015; 41(4):322–6. https://doi.org/10.1136/medethics-2013-101887 PMID:
24872596
217. Rose G. Situating knowledges: positionality, reflexivities and other tactics. Progress in Human Geog-
raphy. 1997; 21(3):305–20.
218. Bernhardt BA, Roche MI, Perry DL, Scollon SR, Tomlinson AN, Skinner D. Experiences with obtaining
informed consent for genomic sequencing. Am J Med Genet A. 2015; 167a(11):2635–46. https://doi.
org/10.1002/ajmg.a.37256 PMID: 26198374
219. Blout C, Christensen K, Perez E, Shah N, Green RC. Biobank set-up and execution: A retrospective
effort analysis. The National Society of Genetic Counselors Virtual Conference2020.
220. Green RC, Blout C, Lebo M, J. K, Smoller J, Karlson E, et al. Returning Unanticipated Genomic
Results in a Hospital-Based Research Biobank. The American Society of Human Genetics Annual
Meeting; San Diego, USA2018.
221. Vears DF, Delany C, Massie J, Gillam L. "They Just Want to Know"—Genetic Health Professionals’
Beliefs About Why Parents Want to Know their Child’s Carrier Status. J Genet Couns. 2017; 26
(6):1314–23. https://doi.org/10.1007/s10897-017-0070-2 PMID: 28161759
222. Mand C, Gillam L, Duncan RE, Delatycki MB. “It was the missing piece”: adolescent experiences of
predictive genetic testing for adult-onset conditions. Genetics in Medicine. 2013; 15(8):643–9. https://
doi.org/10.1038/gim.2013.15 PMID: 23448724
223. Kalia SS, Adelman K, Bale SJ, Chung WK, Eng C, Evans JP, et al. Recommendations for reporting of
secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy
statement of the American College of Medical Genetics and Genomics. Genetics in Medicine. 2017;
19(2):249–55. https://doi.org/10.1038/gim.2016.190 PMID: 27854360
PLOS ONE Systematic review of stakeholder perspectives on return of results
PLOS ONE | https://doi.org/10.1371/journal.pone.0258646 November 8, 2021 71 / 71
